

RealRate

PHARMACEUTICAL 2018

CORCEPT THERAPEUTICS INC Rank 3 of 342









PHARMACEUTICAL 2018



CORCEPT THERAPEUTICS INC Rank 3 of 342



The relative strengths and weaknesses of CORCEPT THERAPEUTICS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of CORCEPT THERAPEUTICS INC compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 181% points. The greatest weakness of CORCEPT THERAPEUTICS INC is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 11% points.

The company's Economic Capital Ratio, given in the ranking table, is 366%, being 320% points above the market average of 46%.

Input Variable	Value in 1000 USD
Assets, Current	124,185
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	29,569
Liabilities, Non-Current	0
Other Assets	95,834
Other Compr. Net Income	-75
Other Expenses	-72,762
Other Liabilities	0
Other Net Income	-49
Other Revenues	159,201
Property and Equipment	518
Research and Development	40,376
Selling, General and Administrative Expense	62,416

Output Variable	Value in 1000 USD
Assets	220,537
Liabilities	29,569
Expenses	30,030
Revenues	159,201
Stockholders Equity	190,968
Net Income	129,122
Comprehensive Net Income	129,084
Economic Capital Ratio	366%

